GO:0015188 L-isoleucine transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015188 describes the molecular function that moves L-isoleucine across a biological membrane, often coupled to sodium or proton gradients.
• The term covers several transporter families, including sodium-coupled symporters and proton-dependent permeases, and is closely related to valine and leucine transport.
• In Escherichia coli K-12, the previously uncharacterized protein YhjE was recently identified as an L-isoleucine and L-valine transporter, filling a gap in branched-chain amino acid uptake.
• Transporters with this activity are frequently members of the amino acid-polyamine-organocation (APC) superfamily or the neurotransmitter:sodium symporter (NSS) family, which share a common structural fold.
• Dysregulation of amino acid transport can influence metabolic reprogramming in cancer and neurological disorders, making these proteins potential therapeutic targets.
• Studying GO:0015188 requires a combination of genetic, biochemical, and structural approaches, including CRISPR knockout, radiolabeled uptake assays, and electrophysiology.
Description
L-isoleucine is an essential branched-chain amino acid that must be acquired from the environment or diet. The molecular function that mediates its movement across cell membranes is annotated as GO:0015188, L-isoleucine transmembrane transporter activity. This activity is fundamental for nutrient uptake, protein synthesis, and metabolic signaling in organisms ranging from bacteria to humans. In bacteria such as Escherichia coli, multiple transport systems contribute to branched-chain amino acid uptake, and the recent identification of YhjE as an L-isoleucine and L-valine transporter highlights that this functional class is still being defined. In eukaryotes, related transporters are critical for amino acid homeostasis in tissues such as the brain and muscle, where isoleucine serves both as a building block and as a signaling molecule. Understanding GO:0015188 therefore bridges basic membrane biology and translational research in metabolism, infectious disease, and cancer.
L-isoleucine transmembrane transporter activity At A Glance
| GO ID | GO:0015188 |
|---|---|
| GO term | L-isoleucine transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | isoleucine/valine:sodium symporter activity; leucine/isoleucine/valine porter activity; leucine/valine/isoleucine permease activity; L-isoleucine transporter activity |
| Major function | Translocation of L-isoleucine across a membrane, often coupled to sodium or proton gradients |
| Related amino acids | L-valine and L-leucine, which share structural similarity and often compete for the same transporters |
| Representative protein | YhjE in Escherichia coli K-12, an L-isoleucine and L-valine transporter |
| Cellular context | Plasma membrane of bacteria, archaea, and eukaryotic cells; also organellar membranes in some cases |
What Is GO:0015188?
GO:0015188, L-isoleucine transmembrane transporter activity, is a molecular function term defined as enabling the transfer of L-isoleucine from one side of a membrane to the other. L-isoleucine is the (2R*,3R*)-2-amino-3-methylpentanoic acid stereoisomer. This activity is typically mediated by integral membrane proteins that couple isoleucine movement to an electrochemical gradient, such as sodium or proton symport, or that facilitate passive transport. The term is distinct from binding or receptor activity because it explicitly requires the translocation of the substrate across a lipid bilayer.
Why Is L-isoleucine transmembrane transporter activity Important in Cell Biology?
GO:0015188 is important because L-isoleucine is an essential amino acid that cannot be synthesized by humans and must be imported. Transporters with this activity control the intracellular availability of isoleucine for protein synthesis and for signaling pathways such as mTORC1. In bacteria, these transporters are virulence factors and drug targets, while in humans, mutations or dysregulation can contribute to metabolic and neurological disorders. The recent discovery of YhjE as a missing L-isoleucine transporter in E. coli demonstrates that even well-studied organisms still harbor uncharacterized components of this activity. Moreover, serum metabolite studies have linked branched-chain amino acid metabolism to diseases such as multiple myeloma, underscoring the clinical relevance of understanding isoleucine transport.
• Provides essential isoleucine for protein synthesis in organisms that cannot synthesize it.
• Contributes to branched-chain amino acid homeostasis and metabolic signaling.
• Represents a target for antibacterial drug development in pathogens.
• Influences cancer cell metabolism, where amino acid uptake is often upregulated.
• Plays a role in neurological function because isoleucine and related amino acids affect neurotransmitter synthesis.
• Helps explain nutrient competition in the gut microbiome and host-microbe interactions.
• Enables metabolic engineering of microorganisms for isoleucine production or consumption.
• Serves as a model for studying membrane protein structure-function relationships.
What Happens During L-isoleucine transmembrane transporter activity?
Substrate recognition and binding
In simple terms: The transporter first grabs the isoleucine molecule from one side of the membrane.
Transporters with GO:0015188 activity possess a substrate-binding site that recognizes L-isoleucine with stereochemical specificity. For sodium-coupled symporters, binding of Na+ ions often precedes or accompanies isoleucine binding, inducing a conformational change that traps the substrate. In E. coli YhjE, this site discriminates between isoleucine and valine, allowing both but excluding other amino acids.
Conformational cycling and translocation
In simple terms: The protein changes shape to carry isoleucine across the membrane.
After binding, the transporter undergoes alternating access transitions: the outward-facing conformation closes and opens inward, releasing isoleucine into the cytoplasm. This cycle is driven by the electrochemical gradient of the coupled ion (e.g., Na+ or H+). The process is reversible under certain conditions, but under physiological gradients it is directional.
Energy coupling and stoichiometry
In simple terms: The transporter uses the energy of sodium or protons flowing into the cell to pull isoleucine in.
Many L-isoleucine transporters are secondary active transporters that couple the downhill movement of Na+ or H+ to the uphill transport of isoleucine. The stoichiometry can vary; for example, some symporters transport one isoleucine with one or more sodium ions. This coupling allows isoleucine to accumulate against its concentration gradient.
Release and resetting
In simple terms: Once inside, the isoleucine is released and the transporter resets for another round.
Following release of isoleucine and the coupled ion into the cytoplasm, the transporter returns to its outward-facing state. This resetting step is often rate-limiting and can be regulated by post-translational modifications or interacting proteins. In bacteria, the expression of such transporters is controlled by amino acid availability.
Key Genes Involved in GO:0015188 L-isoleucine transmembrane transporter activity
The following genes and proteins are representative of L-isoleucine transmembrane transporter activity, based on experimental evidence and functional annotation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| yhjE (E. coli) | L-isoleucine and L-valine transporter | Recently identified missing transporter in E. coli K-12; model for APC superfamily |
| brnQ (E. coli) | Branched-chain amino acid transporter | Transports isoleucine, valine, and leucine; contributes to uptake |
| livJ (E. coli) | Periplasmic binding protein for branched-chain amino acids | Component of the LIV-I transport system; high-affinity uptake |
| livK (E. coli) | Periplasmic binding protein | Part of the LIV-I system; binds isoleucine, valine, leucine |
| livH (E. coli) | Membrane permease | Forms the translocation channel of the LIV-I system |
| livM (E. coli) | Membrane permease | Part of the LIV-I system; couples ATP hydrolysis to transport |
| livG (E. coli) | ATP-binding cassette | Provides energy for LIV-I transport |
| livF (E. coli) | ATP-binding cassette | Part of the LIV-I system; essential for function |
| SLC7A5 (human) | L-type amino acid transporter 1 (LAT1) | Transports large neutral amino acids including isoleucine; linked to cancer |
| SLC7A8 (human) | L-type amino acid transporter 2 (LAT2) | Transports isoleucine and other neutral amino acids |
| SLC3A2 (human) | 4F2hc heavy chain | Chaperone for LAT1 and LAT2; required for plasma membrane localization |
| SLC1A3 (human) | Glutamate transporter EAAT1 | Mutations cause episodic ataxia; may indirectly affect amino acid homeostasis |
| SLC6A19 (human) | B0AT1 neutral amino acid transporter | Transports isoleucine in kidney and intestine; target for metabolic studies |
| SLC38A2 (human) | SNAT2 sodium-coupled neutral amino acid transporter | Transports isoleucine and other small neutral amino acids |
| SLC43A1 (human) | LAT3 large neutral amino acid transporter | Mediates isoleucine uptake in some tissues |
| SLC43A2 (human) | LAT4 large neutral amino acid transporter | Transports isoleucine and other branched-chain amino acids |
| TMEM16A (human) | Calcium-activated chloride channel | Not a direct isoleucine transporter but regulates membrane potential affecting transport |
How Is L-isoleucine transmembrane transporter activity Regulated?
The activity of L-isoleucine transporters is regulated at multiple levels. In bacteria, expression of genes such as yhjE and the liv operon is controlled by the availability of branched-chain amino acids and by global regulators like Lrp and Crp. In mammalian cells, the localization and activity of transporters such as SLC7A5/SLC3A2 are regulated by mTORC1 signaling, which senses intracellular amino acid levels. Post-translational modifications, including phosphorylation and ubiquitination, can alter transporter trafficking and stability. Additionally, the calcium-activated chloride channel TMEM16A can modulate membrane potential and indirectly influence sodium-coupled transport.
L-isoleucine transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC7A5 | Cancer (multiple myeloma, other solid tumors) | Knockout in cancer cell lines; xenograft models |
| SLC3A2 | Cancer, immune disorders | Conditional knockout in mice; overexpression in cell lines |
| SLC1A3 | Episodic ataxia | Point mutation knock-in in mice; patient-derived iPSCs |
| yhjE (E. coli) | Bacterial growth and colonization | Deletion mutant in E. coli K-12; infection models |
| SLC6A19 | Hartnup disorder (neutral aminoaciduria) | Knockout mice; transport assays in oocytes |
Cancer metabolism
Many cancer cells upregulate amino acid transporters to support rapid proliferation. L-isoleucine uptake via transporters such as SLC7A5 and SLC43A2 contributes to mTORC1 activation and protein synthesis. A recent multi-omics Mendelian randomization study identified serum metabolites, including branched-chain amino acids, as causal drivers of multiple myeloma, highlighting the clinical relevance of isoleucine transport.
Neurological disorders
Isoleucine and related amino acids are precursors for neurotransmitter synthesis and influence brain function. Mutations in SLC1A3, a glutamate transporter, cause late-onset episodic ataxia, and altered amino acid transport may contribute to other neurological conditions. Although SLC1A3 is not a direct isoleucine transporter, it illustrates how transport dysfunction can affect neuronal excitability.
Infectious diseases
Bacterial pathogens rely on isoleucine transporters for growth and survival in the host. YhjE and other branched-chain amino acid transporters in E. coli are potential targets for new antibiotics, as inhibiting them could starve bacteria of essential amino acids.
From L-isoleucine transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate transporter reduce isoleucine uptake? | CRISPR knockout cell line or bacterial deletion mutant |
| Does a specific point mutation alter substrate specificity? | Point mutation knock-in via CRISPR in cell lines |
| Can a tagged transporter be used to study localization? | Knock-in of fluorescent or epitope tag |
| Does overexpression of a transporter increase isoleucine influx? | Stable or transient overexpression in mammalian cells |
| Which tissues require a transporter for isoleucine homeostasis? | Tissue-specific conditional knockout mice |
| Can transporter activity be measured in real time? | Electrophysiology or radiolabeled uptake assays |
How to Study the L-isoleucine transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled uptake assay | Intracellular accumulation of L-isoleucine | Kinetic characterization of transporters |
| Electrophysiology | Substrate-induced currents and ion coupling | Electrogenic transporter mechanism |
| CRISPR knockout screen | Genes required for isoleucine uptake or toxicity | Discovery of novel transporters |
| Proteomics | Protein expression and interaction partners | Identifying transporter complexes |
| RNA-seq | Transcriptional response to isoleucine availability | Regulatory network analysis |
| Structural biology (cryo-EM) | Three-dimensional structure of transporter | Mechanistic insights into transport cycle |
| Metabolomics | Intracellular and extracellular metabolite levels | Pathway analysis and biomarker discovery |
| Mendelian randomization | Causal relationships between metabolites and disease | Human genetics of isoleucine metabolism |
Radiolabeled uptake assays
The most direct method to measure L-isoleucine transmembrane transporter activity is to incubate cells or membrane vesicles with radiolabeled [14C]- or [3H]-isoleucine and quantify intracellular accumulation. This assay can be performed in bacteria, cultured cells, or Xenopus oocytes expressing the transporter of interest. It allows determination of kinetic parameters such as Km and Vmax.
Electrophysiology
For electrogenic transporters, two-electrode voltage clamp or patch clamp can measure substrate-induced currents. This approach provides real-time information about stoichiometry, voltage dependence, and ion coupling. It has been used to characterize many sodium-coupled amino acid transporters.
Genetic screens and CRISPR libraries
CRISPR knockout libraries can be used to identify genes required for isoleucine uptake or sensitivity to isoleucine deprivation. For example, a genome-wide screen in E. coli or mammalian cells can reveal transporters and regulatory factors. This method is powerful for discovering previously unannotated transporters like YhjE.
Structural biology and computational modeling
Cryo-electron microscopy and X-ray crystallography can determine the structure of transporters in different conformations. Homology modeling and molecular dynamics simulations complement these efforts by predicting substrate binding and conformational transitions. Such studies help explain how isoleucine is recognized and translocated.
How CRISPR Can Be Used to Study GO:0015188 L-isoleucine transmembrane transporter activity
Knockout
CRISPR knockout of a candidate L-isoleucine transporter gene can abolish uptake and reveal its contribution to cellular isoleucine homeostasis. In E. coli, deletion of yhjE reduced isoleucine uptake, confirming its role. In mammalian cells, knockout of SLC7A5 or SLC3A2 impairs growth under isoleucine-limited conditions.
Point Mutation
Introducing specific point mutations into transporter genes via CRISPR base editing or homology-directed repair allows structure-function studies. For example, mutating residues in the substrate-binding pocket can alter affinity or specificity for isoleucine versus valine.
Knock-in
Knock-in of epitope tags (e.g., FLAG, GFP) or fluorescent proteins enables visualization and purification of transporters. This approach can also be used to create disease-associated mutations in endogenous loci, such as SLC1A3 mutations linked to episodic ataxia.
Overexpression
CRISPR activation (CRISPRa) or stable integration of a transporter cDNA under a strong promoter can achieve overexpression. This is useful for producing sufficient protein for structural studies or for amplifying transport activity in cell-based assays.
How EDITGENE Supports L-isoleucine transmembrane transporter activity Research
Researchers studying L-isoleucine transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in isoleucine uptake, metabolism, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from generating knockout cell lines to performing genome-wide screens.
Contact EDITGENE today to design your custom CRISPR model for L-isoleucine transmembrane transporter activity research.
Frequently Asked Questions About L-isoleucine transmembrane transporter activity
What is GO:0015188?
GO:0015188 is the Gene Ontology molecular function term for L-isoleucine transmembrane transporter activity, which enables the transfer of L-isoleucine across a membrane.
What genes are involved in L-isoleucine transmembrane transporter activity?
Genes include yhjE, brnQ, and the liv operon in E. coli, as well as SLC7A5, SLC3A2, SLC6A19, and SLC43A2 in humans.
What is the function of L-isoleucine transporters?
They mediate the uptake or efflux of L-isoleucine across cell membranes, often coupled to sodium or proton gradients, to support protein synthesis and metabolism.
How is L-isoleucine transport studied?
Common methods include radiolabeled uptake assays, electrophysiology, CRISPR knockout screens, and structural biology.
Is L-isoleucine transport linked to cancer?
Yes, upregulated amino acid transporters such as SLC7A5 can increase isoleucine uptake and support cancer cell growth, and serum isoleucine has been linked to multiple myeloma in genetic studies.
What is the role of YhjE in isoleucine transport?
YhjE is an L-isoleucine and L-valine transporter in E. coli K-12 that was recently identified, filling a gap in branched-chain amino acid uptake.
Can CRISPR be used to study isoleucine transporters?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect transporter function and regulation.
What diseases are associated with defective isoleucine transport?
Disorders include metabolic diseases, neurological conditions such as episodic ataxia linked to SLC1A3 mutations, and cancer.
How does isoleucine transport affect mTOR signaling?
Isoleucine uptake can activate mTORC1, which promotes protein synthesis and cell growth, linking transport activity to nutrient sensing.
What are the synonyms for GO:0015188?
Synonyms include isoleucine/valine:sodium symporter activity, leucine/isoleucine/valine porter activity, leucine/valine/isoleucine permease activity, and L-isoleucine transporter activity.
Conclusion
GO:0015188, L-isoleucine transmembrane transporter activity, is a fundamental molecular function that controls the availability of an essential amino acid. From bacterial nutrient uptake to human cancer metabolism, these transporters play critical roles in health and disease. Recent discoveries such as YhjE in E. coli highlight that even well-studied systems still contain uncharacterized components. Continued research using CRISPR models, structural biology, and functional assays will deepen our understanding of isoleucine transport and may reveal new therapeutic targets.
References
- 1. Molev SV et al.. 2025. Deciphering a missing piece of the branched-chain amino acids uptake puzzle: YhjE is an L-isoleucine and L-valine transporter in Escherichia coli K-12.. Front Microbiol 16:1727951 PMID: 41415815
- 2. Arreola J et al.. 2024. Insights into the function and regulation of the calcium-activated chloride channel TMEM16A.. Cell Calcium 121:102891 PMID: 38772195
- 7. Liu Y et al.. 2026. Integrating Bidirectional Mendelian Randomization with Multi-Omics Reveals Causal Serum Metabolites and Novel Metabolic Drivers of Multiple Myeloma.. Int J Mol Sci 27(4) PMID: 41752037
- 8. Choi KD et al.. 2017. Late-onset episodic ataxia associated with SLC1A3 mutation.. J Hum Genet 62(3):443-446 PMID: 27829685
